Skip to main content
. 2018 Aug 3;9(60):31664–31681. doi: 10.18632/oncotarget.25839

Figure 4.

Figure 4

Our results suggest that the isolated determination of blood hexoses levels is not as informative as the measurement of hexoses levels in relation to other metabolic intermediates and ratios including: i) the mitochondrial carnitine palmitoyltransferase II (CPT II) deficiency ratio (C16/C3) (B Grey elipse) ii)-the peroxisomal impairment biomarkers lysoPC a C26:0, lysoPC a C26:1 and lysoPC a C28:1 (A Grey elipse) and D–E or iii)- its relation to glutaminolysis [Phe/(Gln/Glu)/Asp] (C). Importantly, both CPT II and peroxisomal deficiencies are well known metabolic conditions associated with hypoglycemia in patients afflicted with these rare metabolic disorders. BC, Breast Adenocarcinomas; CRC, Colon Adenocarcinomas; Lung, Lung Adenocarcinomas; HCC, Liver Adenocarcinomass; H.Risk (n = 33), women depicting 1.5 to 1.8 relative risks of breast cancer development; L.Risk, women at lower risks of breast cancer development; PCOS, Polycystic ovary syndrome; From 0 to 5, population-based controls depicting progressive stages of metabolic syndrome; Hem, patients harboring non-glandular tumors leukemias, myelomas and lymphomas; H&N, patients harboring squamous cells carcinomas of head and neck; BC-Lum (n = 104), patients harboring luminal breast tumors; BC-non Lum (n = 50), patients harboring non-luminal breast tumors; In situ (n = 23), patients harboring non-invasive in situ carcinoma *** Indicates p < 0.001.